1[1]Peter MK, Seigo I. Apoptesis and heart failure: a critical review of the literature. Cite Res, 2000, 86: 1107～1113
2[2]Hatmstetter A, Izumo S. Future perspectives and potential implications of cardiac myocyte apoptosis. Cardiovasc Res, 2000, 45(3): 795～801
3[3]Narula J, Kolodgie FD, Virmani R. Apoptosis and cardomyopathy. Curr Opin Cardiol, 2000, 15(3): 183～188
4[4]Okuyama M, Yamagnchi S, Nozaki N et al. Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am J Cardio, 1997, 79: 1698～1701
5[5]Tanaka M,Suda T, Haze K et al. Fas ligand in human serum. Nat Med, 1996, 2: 317～322
6[6]De Maria R, Testi R. Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity, lmmunol Today, 1998, 19: 121～125
7[7]Yamsguchis S, Yamaokam M, Okuyama M. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failur. Am J Cardial, 1999, 83: 1500～1503
8[8]Armin H, Seigo I. Apoptosis: Basic mechanisms and implications for cardiovascular disease. Cire Res, 1998,82(11): 1111～1129
9[9]Brenner B, Ferlinz K, Grassme H et al. Cell Death and Differeatiation, 1998, 5(1): 29～37
10[10]Tanaka M, Ito H, Adachi S et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res, 1994, 75(3): 426～433
2Lee P,Sata M,Lefer DJ,et al.Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo[J].Am J Physiol Heart Circ Physiol,2003,284(2):H456-463.
3Spinale FG.Matrix metalloproteinases:regulation and dysregulation in the failing heart[J].Cir Res,2002,90(5):520-530.
